1Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther, 2002, 301: 418-426.
2Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvemeet over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum, 2004, 50: 1051-1065.
同被引文献16
1Yoshida K,Fukunaga K,Ikeuchi H,et al.Scheduled infliximab monotherapy to prevent recurrence of Crohns disease following ileocolic or ileal resection:a 3-year prospective randomized open trial.Inflamm Bowel Dis,2012,18:1617~1623.
2Herroro E.Habi Cheyn S infliximab[J].Actas Dermosifiliogr,2008,99 Supp 14:7~13.
3Takeuchi T,Tatsuki Y,Nogami Y,et al.Postmarketing Surveillance of safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis Ann Rheum Dis,2008,67:189~194.
4Keane J,Gershon S,Wise RP,et al.Tuberculosi associated with infliximab,a tumor necrosis factor alpha-neutralizing agent[J].N Eng J Med,2001,345(15)1098~1104.
